Portrait of a senior woman standing outdoors on a holiday. Senior woman wearing a backpack and jacket standing during a trekking trip.

Bringing hope through science

Oncopeptides AB (publ) is a biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. We are science driven, entrepreneurial, and committed to bringing innovation to our patients. Our vision is to bring hope to patients through passionate people, innovative science and transformative drugs.

Read more about Oncopeptides

Oncopeptides rights issue 2024

Oncopeptides carries out a 300 million SEK rights issue

Find more information including questions and answers here.

Link to rights issue page, Oncopeptalks, Q&A for investors and recorded webcast

Sofia Heigis presents at BioStock

Biostock investor pitch: Oncopeptides

March 22, 2024 – Sofia Heigis, CEO, presents Oncopeptides to BioStock, Scandinavia’s leading digital news and analysis service with an exclusive focus on companies in the Life Science sector.

More information and watch the presentation

Sofia Heigis presents at Redeye

Sofia Heigis presented at Redeye Commercialization in Life Science event

Oncopeptides’ CEO Sofia Heigis presented at Redeye’s event: Commercialization in Life Science on March 20, 2024.

See the recorded presentation at Redeye

Company news

Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa

March 27, 2024

Oncopeptides AB and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”).

Read more

Oncopeptides receives decision from the U.S. Food and Drug Administration confirming withdrawal of Pepaxto from the U.S. market

February 23, 2024

Oncopeptides AB (publ) today announces that the U.S. Food and Drug Administration (FDA) has made a decision regarding the withdrawal of Pepaxto, which Oncopeptides had appealed.

Read more

Oncopeptides receives positive recommendation for Pepaxti by Spanish Pricing Authority

February 23, 2024

Oncopeptides AB (publ), a biotech company focused on difficult-to-treat cancers, today announces that the Spanish Drug Pricing Authority (CIPM) has published a positive recommendation for the pricing of melflufen, branded in Europe as Pepaxti.

Read more

Science news

Oncopeptides’ PORT study shows peripheral administration of Pepaxti being equally safe as central venous administration

March 1, 2024

Oncopeptides today announces that a new article analyzing scientific data on melflufen, marketed in Europe as Pepaxti, was recently published in the peer-reviewed medical journal Clinical Lymphoma, Myeloma and Leukemia.

Read more

Pepaxti provides sustained health related Quality of Life OCEAN study shows, article published in Haematologica

February 29, 2024

Oncopeptides today announces that a new article analyzing health-related quality of life in patients treated with melflufen, marketed in Europe as Pepaxti, has been published in Haematologica.

Read more

Type IB variation process finalized – original indication remains with peripheral administration included

February 7, 2024

Oncopeptides recently received a favorable opinion from EMA to revert back to the originally approved indication for Pepaxti. This means that the previously communicated decision to opt out of the process to extend the indication has now been fully realized.

Read more

Investor news

Sofia Heigis presents at BioStock

Biostock investor pitch: Oncopeptides

March 22, 2024

Sofia Heigis, CEO, presents Oncopeptides to BioStock, Scandinavia’s leading digital news and analysis service with an exclusive focus on companies in the Life Science sector.

Read more

Sofia Heigis interviewed by Redeye's life science analyst

March 19, 2024

On Monday, Oncopeptides' CEO Sofia Heigis was interviewed by Redeye's life science analyst Richard Ramanius. The conversation touched on, among other things, the recently announced new rights issue, what the European market for multiple myeloma drugs looks like and status on the ongoing commercialization in Europe.

Read more

Sofia Heigis presents at Redeye Commercialization in Life Science event on March 20

March 18, 2024

Oncopeptides’ CEO Sofia Heigis will present at Redeye’s event: Commercialization in Life Science on March 20, 2024.

Read more

Press release - March 27, 2024

Oncopeptides and Vector Pharma FZCO Announce Collaboration to Provide Pepaxti to Patients in the Middle East and North Africa

Read press release
CEO Sofia Heigis - Oncopeptides AB

Released February 27, 2024

Oncopeptides publishes year-end report 2023

Read report

Download

“The fourth quarter sets the stage for revenue acceleration in 2024”

CEO Sofia Heigis

 

See the Webcast

Webcast presentation as pdf

 

For further information, please contact:

David Augustsson
Director Corporate Affairs
david.augustsson@oncopeptides.com
+46 762 29 38 68

 

Oncopeptides AB Q1 interim report 2024 will be published May 30, 2024

Upcoming events

2024-04-15

Extraordinary General Meeting

Meeting

2024-04-22

Annual report 2023

Report

2024-04-29 - 2024-05-29

Silent Period

Other

Senior Hispanic man in wheelchair, with adult son

Vision of Oncopeptides

”Oncopeptides brings hope to patients through passionate people, innovative science and transformative medicines”

Read more about Oncopeptides

Oncopeptides value words inside the logotype

Cultures & Values

We are a science driven, entrepreneurial company, committed to bringing innovation to patients with an unmet medical need, and improving their lives.

Read more

Oncopeptides via e-mail